Search
Asunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigational[L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020. … for progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.
Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationala significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by … gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics
CX-052075
go.drugbank.com/drugs/DB31655Approved[L53408,L53423] The original approval was formulated with the JN.1 strain ([mRNA-1283]), but was ultimately updated to the sublineage LP.8.1.[L54586] … [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna.
Hydromorphone
go.drugbank.com/drugs/DB00327ApprovedIllicitInvestigationalDue to these modifications, it presents a very high potency and comparable side effect profile to the parent compound. … [A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]
Categories: High-risk opioidsGimeracil
go.drugbank.com/drugs/DB09257ApprovedInvestigationalGimeracil's main role within Teysuno is to prevent the breakdown of [DB00544] (5-FU), which helps to maintin high enough concentrations for sustained effect against cancer cells [L933]. … It functions by reversibly and selectively blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU [A31408].
Parathyroid hormone
go.drugbank.com/drugs/DB05829ApprovedInvestigationalPreotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. … Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).
rsPSMA Vaccine
go.drugbank.com/drugs/DB06361ApprovedWithdrawnIn preclinical studies, rsPSMA elicited high-titer antibodies that strongly cross-reacted with prostate cancer cells. [L1039]
Bezlotoxumab
go.drugbank.com/drugs/DB13140Approved[A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191] … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection.